Long-term Efficacy of Neoadjuvant Chemoradiotherapy Plus Surgery for the Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: The NEOCRTEC5010 Randomized Clinical Trial

Hong Yang, Hui Liu, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, Jiaqing Xiang, Yongtao Han, Zhijian Chen, Haihua Yang, Jiaming Wang, Qingsong Pang, Xiao Zheng, Huanjun Yang, Tao Li, Xu Zhang, Qun Li, Geng Wang, Baofu Chen, Teng Mao, Min Kong, Xufeng Guo, Ting Lin, Mengzhong Liu, Jianhua Fu, Hong Yang, Hui Liu, Yuping Chen, Chengchu Zhu, Wentao Fang, Zhentao Yu, Weimin Mao, Jiaqing Xiang, Yongtao Han, Zhijian Chen, Haihua Yang, Jiaming Wang, Qingsong Pang, Xiao Zheng, Huanjun Yang, Tao Li, Xu Zhang, Qun Li, Geng Wang, Baofu Chen, Teng Mao, Min Kong, Xufeng Guo, Ting Lin, Mengzhong Liu, Jianhua Fu

Abstract

Importance: The prognosis of patients with locally advanced esophageal squamous cell carcinoma (ESCC) remains poor after surgery. Neoadjuvant chemoradiotherapy (NCRT) has been shown to potentially improve survival.

Objective: To compare the treatment efficacy of NCRT plus surgery with surgery alone for long-term survival among patients with locally advanced ESCC.

Design, setting, and participants: The Neoadjuvant Chemoradiotherapy for Esophageal Cancer 5010 study was a multicenter open-label randomized phase 3 clinical trial that enrolled patients between June 1, 2007, and December 31, 2014. Follow-up ended on December 31, 2019. The study was conducted at 8 centers in China. A total of 451 patients aged 18 to 70 years with thoracic ESCC stage T1-4N1M0/T4N0M0 were enrolled and randomized. Data were analyzed from December 1, 2019, to June 30, 2020.

Interventions: Patients randomized to receive NCRT plus surgery (NCRT group) received preoperative chemotherapy (25 mg/m2 of vinorelbine on days 1 and 8 and 75 mg/m2 of cisplatin on day 1 or 25 mg/m2 of cisplatin on days 1 to 4) every 3 weeks for 2 cycles and concurrent radiotherapy (40.0 Gy, administered in 20 fractions of 2.0 Gy for 5 days per week) followed by surgery. Patients randomized to receive surgery alone (surgery group) underwent surgery after randomization.

Main outcomes and measures: The primary end point was overall survival in the intention-to-treat population. The secondary end point was disease-free survival.

Results: A total of 451 patients (mean [SD] age, 56.5 [7.0] years; 367 men [81.4%]) were randomized to the NCRT (n = 224) and surgery (n = 227) groups and were eligible for the intention-to-treat analysis. By December 31, 2019, 224 deaths had occurred. The median follow-up was 53.5 months (interquartile range, 18.2-87.4 months). Patients receiving NCRT plus surgery had prolonged overall survival compared with those receiving surgery alone (hazard ratio, 0.74; 95% CI, 0.57-0.97; P = .03), with a 5-year survival rate of 59.9% (95% CI, 52.9%-66.1%) vs 49.1% (95% CI, 42.3%-55.6%), respectively. Patients in the NCRT group compared with the surgery group also had prolonged disease-free survival (hazard ratio, 0.60; 95% CI, 0.45-0.80; P < .001), with a 5-year survival rate of 63.6% (95% CI, 56.0%-70.2%) vs 43.0% (95% CI, 36.0%-49.7%), respectively.

Conclusions and relevance: In this randomized clinical trial, treatment with NCRT plus surgery significantly improved long-term overall survival and disease-free survival and therefore may be considered a standard of care for patients with locally advanced ESCC.

Trial registration: ClinicalTrials.gov Identifier: NCT01216527.

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

Figures

Figure 1.. CONSORT Flow Diagram
Figure 1.. CONSORT Flow Diagram
ESCC indicates esophageal squamous cell carcinoma; NCRT, neoadjuvant chemoradiotherapy.
Figure 2.. Overall Survival
Figure 2.. Overall Survival
Overall survival for the intention-to-treat population. HR indicates hazard ratio; NCRT, neoadjuvant chemoradiotherapy.
Figure 3.. Disease-Free Survival
Figure 3.. Disease-Free Survival
Disease-free survival for patients with margin-zero resection. HR indicates hazard ratio; NCRT, neoadjuvant chemoradiotherapy.

References

    1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
    1. Chen W, Zheng R, Baade PD, et al. . Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-132. doi:10.3322/caac.21338
    1. Herskovic A, Russell W, Liptay M, Fidler MJ, Al-Sarraf M. Esophageal carcinoma advances in treatment results for locally advanced disease: review. Ann Oncol. 2012;23(5):1095-1103. doi:10.1093/annonc/mdr433
    1. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. ; CROSS Study Group . Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16(9):1090-1098. doi:10.1016/S1470-2045(15)00040-6
    1. Sjoquist KM, Burmeister BH, Smithers BM, et al. ; Australasian Gastro-Intestinal Trials Group . Survival after neoadjuvant chemotherapy or chemoradiotherapy for resectable oesophageal carcinoma: an updated meta-analysis. Lancet Oncol. 2011;12(7):681-692. doi:10.1016/S1470-2045(11)70142-5
    1. Apinop C, Puttisak P, Preecha N. A prospective study of combined therapy in esophageal cancer. Hepatogastroenterology. 1994;41(4):391-393.
    1. Walsh TN, Noonan N, Hollywood D, Kelly A, Keeling N, Hennessy TP. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335(7):462-467. doi:10.1056/NEJM199608153350702
    1. Urba SG, Orringer MB, Turrisi A, Iannettoni M, Forastiere A, Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19(2):305-313. doi:10.1200/JCO.2001.19.2.305
    1. Lee JL, Park SI, Kim SB, et al. . A single institutional phase III trial of preoperative chemotherapy with hyperfractionation radiotherapy plus surgery versus surgery alone for resectable esophageal squamous cell carcinoma. Ann Oncol. 2004;15(6):947-954. doi:10.1093/annonc/mdh219
    1. Burmeister BH, Smithers BM, Gebski V, et al. ; Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: a randomised controlled phase III trial. Lancet Oncol. 2005;6(9):659-668. doi:10.1016/S1470-2045(05)70288-6
    1. Tepper J, Krasna MJ, Niedzwiecki D, et al. . Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086-1092. doi:10.1200/JCO.2007.12.9593
    1. Lv J, Cao XF, Zhu B, Ji L, Tao L, Wang DD. Long-term efficacy of perioperative chemoradiotherapy on esophageal squamous cell carcinoma. World J Gastroenterol. 2010;16(13):1649-1654. doi:10.3748/wjg.v16.i13.1649
    1. Mariette C, Dahan L, Mornex F, et al. . Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. J Clin Oncol. 2014;32(23):2416-2422. doi:10.1200/JCO.2013.53.6532
    1. Yang H, Liu H, Chen Y, et al. ; AME Thoracic Surgery Collaborative Group . Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36(27):2796-2803. doi:10.1200/JCO.2018.79.1483
    1. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 6th ed. American Joint Committee on Cancer; 2002.
    1. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events. Version 3. Division of Cancer Treatment and Diagnosis, National Cancer Institute; 2006.
    1. Yang H, Fu JH, Hu Y, et al. . [Neo-adjuvant chemoradiotherapy followed by surgery in treatment of advanced esophageal carcinoma]. Zhonghua Yi Xue Za Zhi. 2008;88(45):3182-3185.
    1. Schoenfeld D. Partial residuals for the proportional hazards regression model. Biometrika. 1982;69(1):239-241. doi:10.1093/biomet/69.1.239
    1. van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. ; CROSS Group . Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074-2084. doi:10.1056/NEJMoa1112088
    1. Ando N, Iizuka T, Ide H, et al. ; Japan Clinical Oncology Group . Surgery plus chemotherapy compared with surgery alone for localized squamous cell carcinoma of the thoracic esophagus: a Japan Clinical Oncology Group Study—JCOG9204. J Clin Oncol. 2003;21(24):4592-4596. doi:10.1200/JCO.2003.12.095
    1. Li B, Hu H, Zhang Y, et al. . Extended right thoracic approach compared with limited left thoracic approach for patients with middle and lower esophageal squamous cell carcinoma: three-year survival of a prospective, randomized, open-label trial. Ann Surg. 2018;267(5):826-832. doi:10.1097/SLA.0000000000002280
    1. Hofstetter W, Swisher SG, Correa AM, et al. . Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236(3):376-384. doi:10.1097/00000658-200209000-00014
    1. Mulligan ED, Dunne B, Griffin M, Keeling N, Reynolds JV. Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol. 2004;30(3):313-317. doi:10.1016/j.ejso.2003.11.009
    1. Leng X, He W, Yang H, et al. . Prognostic impact of postoperative lymph node metastases after neoadjuvant chemoradiotherapy for locally advanced squamous cell carcinoma of esophagus: from the results of NEOCRTEC5010, a randomized multicenter study. Ann Surg. Published online December 17, 2019. doi:10.1097/SLA.0000000000003727
    1. Sutton P, Clark PJ. Neo-adjuvant treatment for oesophageal cancer. 1999;3(4):231-238.
    1. Oppedijk V, van der Gaast A, van Lanschot JJB, et al. . Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in the CROSS trials. J Clin Oncol. 2014;32(5):385-391. doi:10.1200/JCO.2013.51.2186
    1. Yasuda T. Future treatment strategy for esophageal cancer based on prediction of systemic recurrence: significance of pathologic nodal status after neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25(8):2127-2128. doi:10.1245/s10434-018-6544-0
    1. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359(9319):1727-1733. doi:10.1016/S0140-6736(02)08651-8
    1. Allum WH, Stenning SP, Bancewicz J, Clark PI, Langley RE. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J Clin Oncol. 2009;27(30):5062-5067. doi:10.1200/JCO.2009.22.2083
    1. Kelsen DP, Ginsberg R, Pajak TF, et al. . Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339(27):1979-1984. doi:10.1056/NEJM199812313392704
    1. Kelsen DP, Winter KA, Gunderson LL, et al. ; Radiation Therapy Oncology Group; USA Intergroup . Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol. 2007;25(24):3719-3725. doi:10.1200/JCO.2006.10.4760
    1. Nakamura K, Kato K, Igaki H, et al. ; Japan Esophageal Oncology Group/Japan Clinical Oncology Group . Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol. 2013;43(7):752-755. doi:10.1093/jjco/hyt061

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe